Trial Profile
A Randomized, Double-blind, Repeat Dose Cross-over Study to Assess the Bronchodilator Effects of Once Daily QVM149 Following Morning or Evening Dosing for 14 Days Compared to Placebo in Patients With Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2020
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 11 Jun 2019 Results published in the Novartis media release
- 11 Jun 2019 According to a Novartis media release, results from the two phase II studies (NCT03063086 and NCT03108027) showed a significant improvement over the standard treatment.
- 22 May 2019 Results presented in a Sosei Heptares media release.